India Rheumatology Drugs Market Analysis Report [2022-30]

India Rheumatology Drugs Market Analysis

$ 3999

The India Rheumatology Drugs Market is projected to grow from $1.110 Bn in 2022 to $1.743 Bn by 2030, registering a CAGR of 5.80% during the forecast period of 2022-2030. The Indian government is taking steps to improve access to rheumatology treatments by increasing funding for research and development, as well as implementing policies to reduce the cost of these drugs for patients. Some of the key players in the India rheumatology drugs market include Pfizer, Novartis, Johnson & Johnson, Roche, GlaxoSmithKline (GSK), Sanofi

ID: IN10INPH022 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Shivam Zalke

Buy Now

India Rheumatology Drugs Market Executive Summary

The India Rheumatology Drugs Market is projected to grow from $1.110 Bn in 2022 to $1.743 Bn by 2030, registering a CAGR of 5.80% during the forecast period of 2022 - 2030.

The rheumatology drugs market in India is growing due to the increasing prevalence of rheumatoid arthritis and other autoimmune diseases, as well as growing awareness about these conditions. Major players in the market include multinational pharmaceutical companies and domestic generic drug manufacturers. The Indian government is taking steps to improve access to rheumatology treatments by increasing funding for research and development, as well as implementing policies to reduce the cost of these drugs for patients. Despite these efforts, the market faces challenges such as low patient awareness and limited access to treatments in rural areas.

Rheumatology is a medical specialty that deals with the diagnosis and treatment of rheumatic diseases, which are conditions that affect the joints, bones, and muscles. In India, there is a growing demand for rheumatology services due to the increasing prevalence of conditions such as rheumatoid arthritis, lupus, and osteoarthritis. Despite this demand, there is a shortage of trained rheumatologists in India, particularly in rural areas.

The Indian government is taking steps to address this shortage by increasing funding for medical education and training, as well as promoting the development of new treatments for rheumatic diseases. There are also private hospitals and clinics that offer rheumatology services in major cities, but access to these services remains limited for many patients.

Overall, the rheumatology sector in India has significant potential for growth, and there is a need for increased investment in medical education and research to support this growth and improve patient outcomes.

India rheumatology drug market analysis

Market Dynamics

Market Drivers

There are several factors that are driving the growth of the Indian rheumatology drugs market:

Rising incidence of rheumatic diseases: The increasing prevalence of rheumatic diseases such as rheumatoid arthritis, lupus, and osteoarthritis is a major factor driving demand for rheumatology drugs in India
Growing awareness about rheumatic diseases: Increased awareness about these conditions, including the availability of effective treatments, is contributing to the growth of the market
Government initiatives: The Indian government is taking steps to improve access to rheumatology treatments by increasing funding for research and development, as well as implementing policies to reduce the cost of these drugs for patients
Growth of the pharmaceutical industry: The pharmaceutical industry in India is rapidly growing, with multinational pharmaceutical companies and domestic generic drug manufacturers investing in the market
Economic development: The growing economy of India and increased disposable income is leading to increased demand for advanced medical treatments, including rheumatology drugs

These factors are contributing to the growth of the rheumatology drugs market in India, and the trend is expected to continue in the coming years.

Competitive Landscape

International market players are introducing their pharmaceuticals in India, in response to the rising need for antirheumatic medications there, which is fuelling the market's expansion. For instance, Olumiant (baricitinib) was introduced in India in 2018 by Eli Lily and Company (India) in dose forms of 4 mg and 2 mg. It is an oral medicine taken once daily to treat adults with moderate-to-severe active rheumatoid arthritis (RA). The medication can be administered alone or in conjunction with methotrexate. Pfizer Inc., one of the key players in the global market for rheumatic medicine, acquired ReViral, a privately held clinical-stage biopharmaceutical business, in June 2022. ReViral focuses on researching, developing, and commercializing novel antiviral medicines for the respiratory syncytial virus (RSV).

Key Players

Some of the key players in the Indian rheumatology drugs market include:

Pfizer
Novartis
Johnson & Johnson
Roche
GlaxoSmithKline (GSK)
Sanofi
AbbVie
Biocon
Cipla
Dr. Reddy's Laboratories

These are some of the major multinational and domestic pharmaceutical companies that are active in the Indian rheumatology drugs market. They offer a range of innovative and generic drugs for the treatment of rheumatic diseases, and they are well-established in the Indian market.

Healthcare Policies and Regulatory Landscape

In India, the regulatory landscape for rheumatology drugs is governed by the Central Drugs Standard Control Organization (CDSCO), which is the national regulatory body responsible for approving and regulating the marketing and distribution of pharmaceutical products in the country.

The Indian government has implemented several policies aimed at improving access to rheumatology treatments, such as increasing funding for medical research and development, as well as implementing measures to reduce the cost of these drugs for patients. This has led to increased investment in the rheumatology drugs market and the introduction of new, innovative treatments.

In addition, the government has implemented measures to promote the use of generic drugs and encourage their production by domestic manufacturers. This has helped to increase the availability and affordability of rheumatology drugs for patients in India.

Overall, the healthcare policies and regulatory landscape in India are supportive of the growth of the rheumatology drugs market, and they are expected to continue to play a key role in shaping the future of this sector.

In India, reimbursement for rheumatology drugs is provided through a combination of government and private health insurance programs. The government operates the Central Government Health Scheme (CGHS), which provides health insurance coverage for government employees and their families. Some state governments also operate their own health insurance schemes for their employees.

In addition, there are several private health insurance companies in India that offer coverage for rheumatology drugs, either as part of comprehensive health insurance plans or as stand-alone policies. The extent of coverage and the out-of-pocket expenses incurred by patients for rheumatology drugs can vary widely depending on the specific insurance plan and the individual patient's circumstances.

Despite the availability of these reimbursement programs, access to rheumatology treatments remains limited for many patients in India, particularly those in rural areas or with low incomes. Efforts to improve access to these treatments, such as government initiatives to increase funding for medical research and reduce the cost of drugs, are ongoing.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Rheumatology Drug Market Segmentation

Drug Class

The disease-modifying anti-rheumatic drugs (DMARDs) is the major revenue contributor. Rise in awareness related to the use of DMARDs, surge in prevalence of rheumatoid arthritis, rise in obese & overweight population across the globe, and increase in adoption of DMARDs as a first-line treatment for rheumatoid arthritis are the key factors that boost the growth of the segment.

Disease-modifying anti-rheumatic drugs (DMARDs)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Corticosteroids
Uric acids
Others

Route of administration

Oral
Parental

Sales channel

Depending on the sales channel, the prescription-based drug segment is the major shareholder in the India rheumatoid drugs market, owing to the advantages offered by prescription-based drugs.

Prescription-based drugs
OTC

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.